Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Re: "Potential Bias from Unstratified ICS Dose Standardization During the 2‑Week Run‑in Period in the FORCE2 Study" (Miao et al.).
Journal: The Journal of asthma : official journal of the Association for the Care of Asthma
Published: August 13, 2026
Improved lung function with beclomethasone/formoterol versus beclomethasone alone in asthma: the FORCE2 study.
Journal: The Journal of asthma : official journal of the Association for the Care of Asthma
Published: November 13, 2025
Inhaled anti-thymic stromal lymphopoietin antibody fragment, ecleralimab, in severe asthma: A placebo-controlled, multicenter, double-blind, randomized, phase 2b clinical trial.
Journal: American journal of respiratory and critical care medicine
Published: June 20, 2025
Inhaled anti-thymic stromal lymphopoietin antibody fragment, ecleralimab, in severe asthma: A placebo-controlled, multicenter, double-blind, randomized, phase 2b clinical trial.
Journal: American journal of respiratory and critical care medicine
Published: June 20, 2025
Efficacy and safety of inhaled extrafine beclomethasone dipropionate in adults with asthma: a randomized, parallel-group, dose-ranging study (BEAM).
Journal: The Journal of asthma : official journal of the Association for the Care of Asthma
Published: May 25, 2021
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Journal: The journal of allergy and clinical immunology. In practice
Published: October 18, 2017
Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma.
Journal: The Journal of allergy and clinical immunology
Published: May 18, 2017
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.
Journal: Lancet (London, England)
Published: July 15, 2016
The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma.
Journal: Pulmonary pharmacology & therapeutics
Published: December 18, 2015
Recommendations for the pharmacologic management of allergic rhinitis.
Journal: Allergy and asthma proceedings
Published: January 14, 2015
Last Updated: 09/26/2026